TrialJournal of diabetes investigation2019

Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.

Yasuo Terauchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.